Standardized Infliximab Regimen to Treat Severe Central Nervous System Tuberculosis: A Case Series of 18 Patients

20254 citationsJournal Articlegold Open Access

Authors

Johan Benhard · Inserm

Gentiane Monsel · Inserm

Vincent Dubée · Inserm

Patricia Pavèse · Centre Hospitalier Universitaire de Grenoble

Vero Rasoldier · Université de Rouen Normandie

Valérie Garrait · Hôpital Intercommunal de Créteil

Marie Talleux ·

Abstract

Infliximab may represent a promising adjunctive treatment for CNS TB unresponsive to SOC, including paradoxical reaction. Prospective studies are needed to confirm these findings.

Topics & Keywords

Infectious Diseases and Tuberculosis Tuberculosis Research and Epidemiology Bacterial Infections and Vaccines

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Open Forum Infectious Diseases

Volume 12, Issue 8, pp. ofaf450-ofaf450

DOI: 10.1093/ofid/ofaf450

Field-Weighted Citation Impact: 8.04